The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

Ozempic, the GLP-1 drug initially approved by the U.S. Food and Drug Administration in 2017 to treat Type 2 diabetes, was recently OK’d to help reduce risks linked to chronic kidney disease (CKD).

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s diabetes-cum-weight loss drug Ozempic for patients with both chronic kidney disease (CKD) and diabetes after clinical trials ...

The FDA has approved Ozempic to reduce kidney failure risk in people with type 2 diabetes and chronic kidney disease. Studies ...

Smith and Dani Blum Over a decade ago, a smattering of studies suggested that early cousins of drugs like Ozempic and Mounjaro ... including heart and kidney disease. The same dynamic may be ...